The Novo Nordisk and Evotec LAB eN2 – Johns Hopkins University Collaboration supports Johns Hopkins researchers developing targets, disease insights, and tools to advance cardio-metabolic and rare blood disease discoveries.
The Investigator-Sponsored Studies (ISS) Program supports independent researchers conducting clinical and observational studies to address evidence gaps in Novo Nordisk therapeutic areas and improve patient outcomes.
External Collaborative Research (ECR) supports non-commercial sponsors conducting clinical, observational, and health outcomes studies to investigate disease progression, treatments, and patient experience.
Industry Discovery & Development Partnership Program supports companies developing therapeutics and devices through research and clinical trials to advance products that cure, treat, or prevent type 1 diabetes.
NIDDK Early Research Partnership Engagement Challenge supports academic and community partners in early engagement to shape future prevention or treatment research within NIDDK’s mission.
NIDDK plans to fund Diabetes Research Centers (P30) to foster collaboration, mentoring, and innovative research resources for advancing diabetes and metabolic disorder research.